Related Experiment Video
Updated: Jun 9, 2025

Manual Therapy for a Chronic Non-Specific Low Back Pain Rat Model
Published on: August 11, 2023
Duloxetine for individuals with chronic back pain: A systematic review and meta‑analysis of randomized controlled
Duaa Bafail1, Hazem E Mohammed2, Zeyad Bady2
1Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah 23343, Kingdom of Saudi Arabia.
Abstract:
The current study aimed to assess the efficacy of duloxetine in reducing pain and improving the quality of life of individuals with chronic low back pain (CLBP). An extensive literature search was conducted to identify relevant studies that examined the efficacy of duloxetine in CLBP management. The primary objective of the present study was to assess the role of duloxetine use on pain levels, as well as improvements in quality of life, using validated instruments. The results were synthesized using a random-effects model. A total of 8 studies were included in the analysis. Duloxetine demonstrated clear benefits in pain reduction, evidenced by improvements across multiple scales including the visual analogue scale, brief pain inventory-interference (BPI), BPI-severity, weekly worst pain over 24 hours and Roland-Morris Disability Questionnaire scores. Quality of life improved with duloxetine treatment, as indicated by the 36-item short form survey (SF-36). However, there was no significant impact on the physical function component of SF-36. The present study provides evidence to affirm the efficacy of duloxetine in treating CLBP. Further research is required to validate these findings and to establish whether combining duloxetine with other CLBP treatments yields superior outcomes.
More Related Videos
06:28Biomechanical Changes Related to Low Back Pain: An Innovative Tool for Movement Pattern Assessment and Treatment Evaluation in Rehabilitation
Published on: December 13, 2024
05:10Back Mechanical Sensitivity Assessment in the Rat for Mechanistic Investigation of Chronic Back Pain
Published on: August 30, 2022